Stockscreener 앱 받기
6.15
3.89%
0.23
시간 외 거래:
6.15
Upstream Bio Inc 주식(UPB)의 최신 뉴스
Upstream Bio presents positive Phase 2 trial data for verekitug By Investing.com - Investing.com Nigeria
Upstream Bio presents positive Phase 2 trial data for verekitug - Investing.com
Upstream Bio Reports Positive Phase 2 Results for Verekitug in Chronic Rhinosinusitis with Nasal Polyps, Achieving Clinically Meaningful Improvements in Key Symptoms - Quiver Quantitative
Upstream Bio Presents New Responder Analyses Demonstrating Clinically Meaningful Improvements ... - Caledonian Record
Quarterly nasal polyp treatment improved symptoms for most trial patients - Stock Titan
Upstream Bio, Inc. unveils Phase 2 VIBRANT trial data showing majority of verekitug recipients achieve key improvements - Traders Union
Upstream Bio Inc. (UPB) Falls 4.39% as Shares Test Key Support LevelGamma Exposure - newsline.com
UPB Q1 2026 Earnings: Narrower-than-Expected Loss as Clinical Progress ContinuesEarnings Power Value - newsline.com
Upstream Bio Cut to Neutral From Overweight by JP Morgan - Moomoo
Upstream Bio lead drug pivotal trial plan follows strong phase 2 data - MSN
JPMorgan Downgrades Upstream Bio to Neutral From Overweight, Cuts Price Target to $8 From $35 - marketscreener.com
JPMorgan downgrades Upstream Bio stock rating on execution risks By Investing.com - Investing.com Australia
J.P. Morgan Downgrades UpStream Bio(UPB.US) to Hold Rating, Announces Target Price $8 - Moomoo
UPB News | UPSTREAM BIO INC (NASDAQ:UPB) - ChartMill
Why Did UPB Stock Plunge 40% Today? - Stocktwits
Upstream Bio Shareholders Elect Directors, Ratify 2026 Auditor - TipRanks
Upstream Bio, Inc. leadership to share strategy at major Goldman Sachs event - Traders Union
Upstream Bio (UPB) Declines 4% as Shares Approach Key Support at $6.42Thematic ETF Flow - newsline.com
Upstream Bio to Showcase Additional Efficacy Data from the Phase 2 VIBRANT Trial of Verekitug in CRSwNP in Oral Session at EAACI 2026 - markets.businessinsider.com
Upstream Bio to present verekitug trial data at medical congress By Investing.com - Investing.com Australia
Upstream Bio to present verekitug trial data at medical congress - Investing.com
Upstream Bio, Inc. to present new Phase 2 VIBRANT trial data for verekitug at EAACI2026 - Traders Union
Upstream Bio To Showcase Additional Efficacy Data From The Phase 2 Vibrant Trial Of Verekitug In Crswnp In Oral Session At Eaaci 2026 - TradingView
Nasal polyp drug Verekitug Phase 2 data to be aired at EAACI 2026 - Stock Titan
Upstream Bio Inc. (UPB) Q1 2026 Earnings: Narrower-Than-Expected Loss Fails to Spark Investor ConfidenceFinancial Data - newsline.com
Upstream Bio (UPB) Edges Lower as Shares Test Key Support ZoneFundamentals - newsline.com
Upstream Bio (UPB) price target decreased by 18.03% to 51.00 - MSN
Upstream Bio schedules fireside chat at global healthcare event - Traders Union
H.C. Wainwright Initiates UpStream Bio(UPB.US) With Buy Rating, Announces Target Price $36 - Moomoo
UPB Initiates Coverage On HC Wainwright & Co. -- Rating Set to B - GuruFocus
UPB Initiates Coverage On HC Wainwright & Co. -- Rating Set to Buy - GuruFocus
Upstream Bio to Present at the Goldman Sachs 47th Annual Global Healthcare Conference - markets.businessinsider.com
H.C. Wainwright initiates Upstream Bio stock coverage with buy rating By Investing.com - Investing.com Canada
Upstream Bio: The Reset Is The Opportunity, Initiating At Buy (NASDAQ:UPB) - Seeking Alpha
Upstream Bio Inc. (UPB) Q1 2026 Earnings: Narrower-than-expected loss as clinical pipeline progressesEarnings Cycle Report - newsline.com
Upstream Bio (UPB) price target decreased by 10.31% to 44.37 - MSN
Upstream Bio (UPB) Edges Higher Amid Quiet Trading, Holds Above Key SupportSupply Zone - The Legal Advocate
Upstream Bio Q1 2026 Earnings: Narrower-than-Expected Loss Amid Clinical ProgressEarnings Surprise Score - The Legal Advocate
Upstream Bio Inc. (UPB) Q1 2026 Earnings: Narrowed Loss Per Share as Clinical Pipeline AdvancesEPS Growth Rate - The Legal Advocate
Upstream Bio Inc. (UPB) Q1 2026 Earnings: Narrower Than Expected Loss Reflects Operational DisciplineAI Trading Community - Newser
Upstream Bio (UPB) Q1 2026 Earnings: Narrower-Than-Expected Loss Amid No Revenue; Stock Edges LowerForward EPS Estimate - Newser
2.60%
0.94%
자본화:
|
볼륨(24시간):